Michelle Monk: Angelina Jolie’s Breasts Part of Massive PR Scheme to Protect Patents, Coinciding with Supreme Court Decision?

0Shares

Angelina Jolie part of a clever corporate scheme to protect billions?

EXPOSED: Angelina Jolie part of a clever corporate scheme to protect billions in BRCA gene patents, influence Supreme Court decision (opinion)

Mike Adams, Editor

NaturalNews.com, 16 May 2013

(NaturalNews) Angelina Jolie's announcement of undergoing a double mastectomy (surgically removing both breasts) even though she had no breast cancer is not the innocent, spontaneous, “heroic choice” that has been portrayed in the mainstream media. Natural News has learned it all coincides with a well-timed for-profit corporate P.R. campaign that has been planned for months and just happens to coincide with the upcoming U.S. Supreme Court decision on the viability of the BRCA1 patent.

This is the investigation the mainstream media refuses to touch. Here, I explain the corporate financial ties, investors, mergers, human gene patents, lawsuits, medical fear mongering and thetrillions of dollars that are at stake here. If you pull back the curtain on this one, you find far more than an innocent looking woman exercising a “choice.” This is about protecting trillions in profits through the deployment of carefully-crafted public relations campaigns designed to manipulate the public opinion of women.

. . . . . . . .

Angelina Jolie's announcement and all its carefully-crafted language had four notable immediate impacts:

1) It caused women everywhere to be terrified of breast cancer through the publishing of false statistics that drove fear into the hearts of anyone with breasts. (See below for explanation.)

2) It caused women to rush out and seek BRCA1 gene testing procedures. These tests just happen to be patented by a for-profit corporation called “Myriad Genetics.” Because of this patent, BRCA1 tests can cost $3,000 – $4,000 each. The testing alone is a multi-billion-dollar market, but only if the patent is upheld in an upcoming Supreme Court decision (see below).

3) It caused the stock price of Myriad Genetics (MYGN) to skyrocket to a 52-week high. “Myriad's stock closed up 3% Tuesday, following the publication of the New York Times op-ed,” wrote Marketwatch.com.4) It drove public opinion to influence the upcoming U.S. Supreme Court decision to rule in favor of corporate ownership of human genes (see more below).Read full article.

Phi Beta Iota: There is some question as to whether she actually has the condition, or will actually have the double-masectomy. In the immediate aftermath of the publicity, questions were raised as to whether the statue of Angelina Jolie breast feeding two infants (see image, we do not make this stuff up) would be modified at the expense of Myriad Genetics. There was also a claim that Henry Kissinger has bid $1 million for the two breasts if they are cut off, to be bronzed and placed with his other memorabilia.

See Also:

Angelina Jolie Breast-Feeding Sculpture